Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
TransCode Therapeutics (RNAZ)
NASDAQ:RNAZ
RESEARCH TOOLSreports
Holding RNAZ?
Track your performance easily
RNAZ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.16 - $288.68
Previous Close$7.53
Volume26.70K
Average Volume (3M)48.71K
Market Cap
$5.24M
Enterprise Value$2.07M
Total Cash (Recent Filing)$3.40M
Total Debt (Recent Filing)$227.25K
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Mar 28, 2025EPS Estimate
-$9.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-265.83
Shares Outstanding696,233
10 Day Avg. Volume43,347
30 Day Avg. Volume48,711
Standard Deviation0.48
R-Squared0.00325
Alpha-0.10
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)4.45
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.12
Forecast
1Y Price Target
$99.00Price Target Upside1071.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
TransCode Therapeutics News
PremiumCompany Announcements
TransCode Therapeutics Raises $8M in Private Placement
PremiumCompany Announcements
TransCode Therapeutics Announces Reverse Stock Split
PremiumCompany Announcements
Transcode Therapeutics Reports Increased Losses Amid Funding Challenges
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company is advancing to dose level 2 of the Phase 1 study evaluating TTX-MC138 for the treatment of solid tumors, following unanimous approval from the Safety Review Committee based on favorable safety results.
Funding And GrantsAn NIH grant of $2M was awarded to the company to assist in funding the trial, highlighting the innovative potential of TransCode's novel RNA technology for the treatment of metastatic cancer.
Novel TreatmentTTX-MC138 has shown potential for unique properties in the treatment of solid tumors, delivering drugs directly to metastatic lesions while sparing normal tissues, which could represent a breakthrough in cancer treatment.
Bears Say
Clinical Program RisksRisks include safety signals emerging with any of the company’s clinical or preclinical programs and efficacy from clinical programs being lower than expected.
Financial PerformanceThe company reported operating expenses significantly lower by 58% due to prioritizing development on the Phase 1 for TTX-MC138 and de-prioritizing other programs.
Stock Listing RiskThere is a de-listing risk if shares go under $1.
---
Ownership Overview
8.49%
Insiders
5.43% Mutual Funds
18.79% Other Institutional Investors
67.29% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RNAZ FAQ
What was TransCode Therapeutics’s price range in the past 12 months?
TransCode Therapeutics lowest stock price was $7.16 and its highest was $288.68 in the past 12 months.
What is TransCode Therapeutics’s market cap?
Currently, no data Available
When is TransCode Therapeutics’s upcoming earnings report date?
TransCode Therapeutics’s upcoming earnings report date is Mar 28, 2025 which is in 96 days.
How were TransCode Therapeutics’s earnings last quarter?
TransCode Therapeutics released its earnings results on Nov 11, 2024. The company reported -$5.28 earnings per share for the quarter, beating the consensus estimate of -$16.17 by $10.89.
Is TransCode Therapeutics overvalued?
According to Wall Street analysts TransCode Therapeutics’s price is currently Undervalued.
Does TransCode Therapeutics pay dividends?
TransCode Therapeutics does not currently pay dividends.
What is TransCode Therapeutics’s EPS estimate?
TransCode Therapeutics’s EPS estimate is -$9.9.
How many shares outstanding does TransCode Therapeutics have?
TransCode Therapeutics has 696,233 shares outstanding.
What happened to TransCode Therapeutics’s price movement after its last earnings report?
TransCode Therapeutics reported an EPS of -$5.28 in its last earnings report, beating expectations of -$16.17. Following the earnings report the stock price went down -12.067%.
Which hedge fund is a major shareholder of TransCode Therapeutics?
Currently, no hedge funds are holding shares in RNAZ
---
TransCode Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$99.00 (1071.60% Upside)
$99.00 (1071.60% Upside)
Blogger Sentiment
Bullish
RNAZ Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-97.23%
12-Months-Change
Fundamentals
Return on Equity
-490.03%
Trailing 12-Months
Asset Growth
-61.52%
Trailing 12-Months
Company Description
TransCode Therapeutics
TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.
---
RNAZ Stock 12 Month Forecast
Average Price Target
$99.00
▲(1071.60% Upside)
Technical Analysis
Best Analysts Covering RNAZ
1 Year
1 Year Success Rate
0/14 ratings generated profit
1 Year Average Return
-73.70%
reiterated a buy rating last month
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -73.70% per trade.
---